ACC

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Retrieved on: 
Monday, March 25, 2024
Moyamoya disease, Cardiovascular disease, Congress, Risk, Patient, NAMS, American College, Ezetimibe, Clinical trial, FDC, ACC, ASCVD

ROSE2 evaluated obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy; full results from the trial were previously presented at the National Lipid Association Scientific Sessions in June 2023.

Key Points: 
  • ROSE2 evaluated obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy; full results from the trial were previously presented at the National Lipid Association Scientific Sessions in June 2023.
  • At ACC, NewAmsterdam will share new data demonstrating obicetrapib and ezetimibe’s impact on small dense LDL-C, a robust predictor of residual risk of future cardiovascular events.
  • NewAmsterdam recently initiated TANDEM, a pivotal Phase 3 clinical trial to evaluate obicetrapib and ezetimibe FDC (‘fixed-dose combination”) in adult patients with Heterozygous Familial Hypercholesterolemia (“HeFH”) and/or Atherosclerotic Cardiovascular Disease (“ASCVD”) or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies.
  • Details of the presentation are as follows:
    Presentation at the 2024 American College of Cardiology (ACC) Congress:

First partial driving automation safeguard ratings show industry has work to do

Retrieved on: 
Tuesday, March 12, 2024
Automation, Volvo, Lexus, Silver, Ford Mustang Mach-E, Environment, Team sport, Name, SOS, Risk, Insurance, Education, Mercedes-Benz, Supercruise, Research, Navi, Software, Ford, Emergency, Death, Brazilian jiu-jitsu ranking system, FEC, AEB, S90, BMW, Ford Mustang, Tesla Model 3, Partial, Radar, Mercedes-Benz C-Class, Safety, Injury, Mobile, Tesla Autopilot, Hertz, Ariya, Adaptive cruise control, ACC, General Motors, Nissan Ariya, GMC Sierra, IIHS, Road

“We evaluated partial automation systems from BMW, Ford, General Motors, Genesis, Lexus, Mercedes-Benz, Nissan, Tesla and Volvo,” IIHS President David Harkey said.

Key Points: 
  • “We evaluated partial automation systems from BMW, Ford, General Motors, Genesis, Lexus, Mercedes-Benz, Nissan, Tesla and Volvo,” IIHS President David Harkey said.
  • The GMC Sierra and Nissan Ariya are both available with partial automation systems that earn marginal ratings.
  • “Some drivers may feel that partial automation makes long drives easier, but there is little evidence it makes driving safer,” Harkey said.
  • “These results are worrying, considering how quickly vehicles with these partial automation systems are hitting our roadways,” Harkey said.

Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy

Retrieved on: 
Wednesday, April 3, 2024
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, Deep learning, FACC, Harvard Medical School, Machine learning, Cone Health Women's Hospital, PPV, Innovation, Algorithm, Artificiality, Assistant, Disease, Associate, Patient, Atlantic Health System, Triage, Salem Hospital, AI, Viz, American College, Massachusetts General Hospital, HCM, Hospital, Hypertrophic cardiomyopathy, Senior counsel, Sports cardiology, Hypertrophy, Medical director, Probability, FDA, ACC, ECG, Mass, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.
  • The Viz HCM module is the first and only AI algorithm cleared by the FDA for HCM.
  • The study found that Viz HCM performance in suspected HCM detection was consistent across various racial backgrounds with a sensitivity of 68.4% and specificity of 99.1%.
  • This validates the effectiveness of relevance score sorting for prioritizing higher probability HCM-positive patients identified by deep-learning algorithms analyzing ECG data.

GE HealthCare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

Retrieved on: 
Wednesday, April 3, 2024
Technology, Mobile, Wireless, Health, Apps, Applications, Radiology, Professional Services, Artificial Intelligence, Medical Devices, Software, Hospitals, Data Analytics, Health Technology, Data Management, Cardiology, Diagnosis, Cardiovascular disease, Prevalence, CVD, Intelligence, Patient, Acquisition, Death, Master of Science, LVEF, Caption, American College, GE HealthCare, Heart, Atrial fibrillation, ACC, Medical imaging

GE HealthCare (Nasdaq: GEHC) today announced the launch of Caption AI artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care on Vscan Air SL.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) today announced the launch of Caption AI artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care on Vscan Air SL.
  • Now, with Caption AI technology, clinicians using Vscan Air SL handheld ultrasound will have access to real-time, step-by-step guidance to capture diagnostic-quality images and automated ejection fraction estimation to help inform clinical decisions across cardiac settings.
  • Vscan Air SL with Caption AI is designed to lower the threshold for healthcare professionals to be able to capture cardiac images so that even non-expert ultrasound users can take a quick look at patients’ hearts.
  • "The integration of Caption AI with the Vscan Air SL handheld ultrasound opens an entirely new chapter for cardiac screening.

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, Pharmacology, Congress Center, Edgewise, Patient, Heart, Heart failure, American College, HCM, Therapy, ACC, Cardiomyopathy, Pharmaceutical industry

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology's Annual Scientific Session (ACC.24).

Key Points: 
  • Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology's Annual Scientific Session (ACC.24).
  • The conference will take place in Atlanta, GA at the Georgia World Congress Center from April 6-8, 2024.
  • “EDG-7500 is a novel investigational therapy for the treatment of HCM with a differentiated mechanism of action,” said Kevin Koch, Ph.D., President and Chief Executive Officer, Edgewise Therapeutics.
  • “Importantly, in our preclinical studies, EDG-7500 has shown potent gradient reduction, normalization of hyperdynamic contractility, and significant improvements in ventricular filling.

SLB Announces Agreement to Acquire Majority Ownership in Aker Carbon Capture

Retrieved on: 
Wednesday, March 27, 2024
Energy, Other Energy, Environment, Carbon, CCUS, International Energy Agency, NOK, IEA, ACC, CO2, Economics, Renewable energy

SLB (NYSE: SLB) today announced an agreement to combine its carbon capture business with Aker Carbon Capture (ACC) to support accelerated industrial decarbonization at scale.

Key Points: 
  • SLB (NYSE: SLB) today announced an agreement to combine its carbon capture business with Aker Carbon Capture (ACC) to support accelerated industrial decarbonization at scale.
  • Bringing together complementary technology portfolios, leading process design expertise and an established project delivery platform, the combination will leverage ACC’s commercial carbon capture product offering and SLB’s new technology developments and industrialization capability.
  • It will create a vehicle for accelerating the introduction of disruptive early-stage technology into the global market on a commercial, proven platform.
  • We are excited to create this business with ACC to accelerate the deployment of carbon capture technologies that will shift the economics of carbon capture across high-emitting industrial sectors.”
    SLB will pay NOK 4.12 billion to purchase 80% of Aker Carbon Capture Holding AS (ACCH), which holds the business of ACC, and will contribute the SLB carbon capture business to the combined entity.

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio

Retrieved on: 
Monday, March 25, 2024
Health, Clinical Trials, General Health, Pharmaceutical, Cardiology, Biotechnology, BMY, Patient, Mitigation, Bristol Myers Squibb, MD, Senior, LVEF, American College, Safety, REMS, ACC, Risk, Hospital, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place April 6-8, 2024 in Atlanta, Georgia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place April 6-8, 2024 in Atlanta, Georgia.
  • These data are consistent with the clinical development program and reinforce the safety profile of CAMZYOS in clinical practice.
  • This effectiveness and safety information about ELIQUIS use in clinical practice can supplement data from randomized clinical trials.
  • Visit this page on BMS.com for more information on Bristol Myers Squibb’s scientific approach and resources on cardiovascular diseases.

MACOM to Showcase 200G per Lane Products at Optical Fiber Communication Conference and Exhibition (OFC)

Retrieved on: 
Thursday, March 21, 2024
Technology, Semiconductor, Security, Satellite, Photography, Telecommunications, Nanotechnology, Software, Audio, Video, VoIP, Networks, Internet, Mobile, Wireless, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, Cloud, Optics, Conference, DSP, MSA, DRIVE, LPO, Copper, AEC, PURE, DAC, Ecosystem, PON, TB, ACC, Data-rate units, TIDEL Park Coimbatore, Mobile phone

MACOM Technology Solutions Inc. (“MACOM”) today announced that it will host live demonstrations of its products at the Optical Fiber Communication Conference and Exposition (“OFC”) in San Diego, California, March 26 – 28, 2024, Booth #3025.

Key Points: 
  • MACOM Technology Solutions Inc. (“MACOM”) today announced that it will host live demonstrations of its products at the Optical Fiber Communication Conference and Exposition (“OFC”) in San Diego, California, March 26 – 28, 2024, Booth #3025.
  • These demonstrations feature advancements in 200G per lane technology, along with new product additions to its portfolio of optical, high-speed analog and mixed signal solutions.
  • 200G per Lane Live Demonstrations Include:
    MACOM PURE DRIVETM 200 Gbps per Lane Linear Drive: MACOM is extending the capabilities of its MACOM PURE DRIVE portfolio to 212 Gbps per lane to enable the development of 1.6TB linear pluggable optical (“LPO”) modules.
  • MACOM PURE DRIVE removes DSP from optical modules and provides industry-leading low power, low latency solutions for optical communications for both single-mode and multi-mode fibers.

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

Retrieved on: 
Wednesday, March 20, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Clinical Trials, Q&A, Medication, Webcast, Alnylam Pharmaceuticals, Angiotensin, American College, RNA interference, Therapy, AGT, ACC, Cardiomyopathy, Hypertension

The event will include presentations and a Q&A session with Alnylam management and Akshay Desai, M.D., Director of the Cardiomyopathy and Heart Failure Program, Brigham and Women’s Hospital.

Key Points: 
  • The event will include presentations and a Q&A session with Alnylam management and Akshay Desai, M.D., Director of the Cardiomyopathy and Heart Failure Program, Brigham and Women’s Hospital.
  • A replay of the call will be available two hours after the call and archived on the same webpage for six months.
  • A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events .
  • An archived webcast will be available on the Company’s website approximately two hours after the event.

Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology’s 73rd Annual Scientific Session

Retrieved on: 
Thursday, March 14, 2024
Other Health, Software, General Health, Data Management, Medical Devices, Technology, Artificial Intelligence, Health Technology, Cardiology, Biotechnology, Other Technology, Health, Cardio, Genomics, Organization, Cardiovascular disease, ACI, Entrepreneurship, Patient, Artificial intelligence, Medicine, CHD, American College, Heart, Epigenomics, Moyamoya disease, ACC, Pharmaceutical industry

Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All."

Key Points: 
  • Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All."
  • All attendees including providers, provider organizations and potential industry partners will be able to learn more about Cardio Diagnostics' HeartRisk and Actionable Clinical Intelligence platforms at booth 3605.
  • Actionable Clinical Intelligence V.3: Building upon the success of its predecessor, which debuted at ACC in 2023, Actionable Clinical Intelligence V.3 takes precision medicine to new heights.
  • "Our new innovative solutions, HeartRisk and Actionable Clinical Intelligence V.3, can potentially revolutionize how healthcare professionals approach cardiovascular disease prevention, detection and management.